BH3 profiling reveals selectivity by herpesviruses for specific Bcl-2 proteins to mediate survival of latently infected cells

Journal of Virology

Volumn 89, Issue 10, 2015, Pages 5739-5746

  Cojohari, Olesea ^a   Burrer, Christine M ^a   Peppenelli, Megan A ^a   Abulwerdi, Fardokht A ^b   Nikolovska Coleska, Zaneta ^b   Chan, Gary C ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; PROTEIN BCL 2; VIRUS PROTEIN;

ARTICLE; BINDING AFFINITY; BINDING SITE; CELL FUNCTION; CELL SURVIVAL; CELL VIABILITY; HERPESVIRIDAE; HUMAN; IMMUNE RESPONSE; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY ANALYSIS; VIRUS IDENTIFICATION; VIRUS LATENCY; AMINO ACID SEQUENCE; APOPTOSIS; CELL LINE; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; GENETICS; HERPES VIRUS INFECTION; HOST PATHOGEN INTERACTION; HUMAN HERPESVIRUS 8; METABOLISM; MOLECULAR GENETICS; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; PROTEIN MICROARRAY; VIROLOGY;

HUMAN HERPESVIRUS 4; HUMAN HERPESVIRUS 5; HUMAN HERPESVIRUS 8;

AMINO ACID SEQUENCE; APOPTOSIS; CELL LINE; CELL SURVIVAL; CYTOMEGALOVIRUS; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HERPESVIRUS 8, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN ARRAY ANALYSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; VIRAL PROTEINS; VIRUS LATENCY;

EID: 84928568973     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00236-15     Document Type: Article

References (63)

1. Bolovan-Fritts CA, Mocarski ES, Wiedeman JA. 1999. Peripheral blood CD14(+) cells from healthy subjects carry a circular conformation of latent cytomegalovirus genome. Blood 93:394-398.
2. Mendelson M, Monard S, Sissons P, Sinclair J. 1996. Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors. J Gen Virol 77:3099-3102. http://dx.doi.org/10.1099/0022-1317-77-12-3099.
3. Taylor-Wiedeman J, Sissons P, Sinclair J. 1994. Induction of endogenous human cytomegalovirus gene expression after differentiation of monocytes from healthy carriers. J Virol 68:1597-1604.
4. Söderberg-Nauclér C, Fish KN, Nelson JA. 1997. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 91:119-126. http://dx.doi.org/10.1016/S0092-8674(01)80014-3.
5. Miyashita EM, Yang B, Babcock GJ, Thorley-Lawson DA. 1997. Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J Virol 71:4882-4891.
6. Miyashita EM, Yang B, Lam KM, Crawford DH, Thorley-Lawson DA. 1995. A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell 80:593-601. http://dx.doi.org/10.1016/0092-8674(95)90513-8.
7. Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA. 1998. EBV persistence in memory B cells in vivo. Immunity 9:395-404. http://dx.doi.org/10.1016/S1074-7613(00)80622-6.
8. Du MQ, Liu H, Diss TC, Ye H, Hamoudi RA, Dupin N, Meignin V, Oksenhendler E, Boshoff C, Isaacson PG. 2001. Kaposi sarcomaassociated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 97:2130-2136. http://dx.doi.org/10.1182/blood.V97.7.2130.
9. Chen L, Lagunoff M. 2005. Establishment and maintenance of Kaposi's sarcoma-associated herpesvirus latency in B cells. J Virol 79:14383-14391. http://dx.doi.org/10.1128/JVI.79.22.14383-14391.2005.
10. Romee R, DiPersio JF. 2014. CMV prophylaxis in hematopoietic-cell transplantation. N Engl J Med 371:576. http://dx.doi.org/10.1056/NEJMc1406756.
11. van der Bij W, Speich R. 2001. Management of cytomegalovirus infection and disease after solid-organ transplantation. Clin Infect Dis 33(Suppl 1):S32-S37. http://dx.doi.org/10.1086/320902.
12. Razonable RR, Paya CV, Smith TF. 2002. Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients. J Clin Microbiol 40: 746-752. http://dx.doi.org/10.1128/JCM.40.3.746-752.2002.
13. Booss J, Dann PR, Griffith BP, Kim JH. 1989. Host defense response to cytomegalovirus in the central nervous system. Predominance of the monocyte. Am J Pathol 134:71-78.
14. Rollag H, Asberg A, Ueland T, Hartmann A, Jardine AG, Humar A, Pescovitz MD, Bignamini AA, Aukrust P. 2012. Treatment of cytomegalovirus disease in solid organ transplant recipients: markers of inflammation as predictors of outcome. Transplantation 94:1060-1065. http://dx.doi.org/10.1097/TP.0b013e31826c39de.
15. Sagedal S, Nordal KP, Hartmann A, Degre M, Holter E, Foss A, Osnes K, Leivestad T, Fauchald P, Rollag H. 2000. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 70:1166-1174. http://dx.doi.org/10.1097/00007890-200010270-00007.
16. Thompson MP, Kurzrock R. 2004. Epstein-Barr virus and cancer. Clin Cancer Res 10:803-821. http://dx.doi.org/10.1158/1078-0432.CCR-0670-3.
17. Kaplan LD. 2013. Human herpesvirus-8: Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma. Hematology Am Soc Hematol Educ Program 2013:103-108. http://dx.doi.org/10.1182/asheducation-2013.1.103.
18. Rudin CM, Thompson CB. 1997. Apoptosis and disease: regulation and clinical relevance of programmed cell death. Annu Rev Med 48:267-281. http://dx.doi.org/10.1146/annurev.med.48.1.267.
19. Chan G, Nogalski MT, Bentz GL, Smith MS, Parmater A, Yurochko AD. 2010. PI3K-dependent upregulation of Mcl-1 by human cytomegalovirus is mediated by epidermal growth factor receptor and inhibits apoptosis in short-lived monocytes. J Immunol 184:3213-3222. http://dx.doi.org/10.4049/jimmunol.0903025.
20. Reeves MB, Breidenstein A, Compton T. 2012. Human cytomegalovirus activation of ERK and myeloid cell leukemia-1 protein correlates with survival of latently infected cells. Proc Natl Acad Sci U S A 109:588-593. http://dx.doi.org/10.1073/pnas.1114966108.
21. Poole E, McGregor Dallas SR, Colston J, Joseph RS, Sinclair J. 2011. Virally induced changes in cellular microRNAs maintain latency of human cytomegalovirus in CD34+ progenitors. J Gen Virol 92:1539-1549. http://dx.doi.org/10.1099/vir.0.031377-0.
22. Wang S, Rowe M, Lundgren E. 1996. Expression of the Epstein Barr virus transforming proteinLMP1causes a rapid and transient stimulation of the Bcl-2 homologue Mcl-1 levels in B-cell lines. Cancer Res 56:4610-4613.
23. Kim JH, Kim WS, Park C. 2012. Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1. Leuk Lymphoma 53:1586-1591. http://dx.doi.org/10.3109/10428194.2012.659736.
24. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E, Rickinson A. 1991. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65:1107-1115. http://dx.doi.org/10.1016/0092-8674(91)90007-L.
25. Portis T, Longnecker R. 2004. Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway. Oncogene 23:8619-8628. http://dx.doi.org/10.1038/sj.onc.1207905.
26. Gao J, Cai Q, Lu J, Jha HC, Robertson ES. 2011. Upregulation of cellular Bcl-2 by the KSHV encoded RTA promotes virion production. PLoS One 6:e23892. http://dx.doi.org/10.1371/journal.pone.0023892.
27. Graham C, Matta H, Yang Y, Yi H, Suo Y, Tolani B, Chaudhary PM. 2013. Kaposi's sarcoma-associated herpesvirus oncoprotein K13 protects against B cell receptor-induced growth arrest and apoptosis through NF-κB activation. J Virol 87:2242-2252. http://dx.doi.org/10.1128/JVI.01393-12.
28. Bellows DS, Howell M, Pearson C, Hazlewood SA, Hardwick JM. 2002. Epstein-Barr virus BALF1 is a BCL-2-like antagonist of the herpesvirus antiapoptotic BCL-2 proteins. J Virol 76:2469-2479. http://dx.doi.org/10.1128/jvi.76.5.2469-2479.2002.
29. Sarid R, Sato T, Bohenzky RA, Russo JJ, Chang Y. 1997. Kaposi's sarcoma-associated herpesvirus encodes a functional bcl-2 homologue. Nat Med 3:293-298. http://dx.doi.org/10.1038/nm0397-293.
30. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, Letai A. 2006. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9:351-365. http://dx.doi.org/10.1016/j.ccr.2006.03.027.
31. Del Gaizo Moore V, Letai A. 2013. BH3 profiling-measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett 332:202-205. http://dx.doi.org/10.1016/j.canlet.2011.12.021.
32. Ni Chonghaile T, Letai A. 2008. Mimicking the BH3 domain to kill cancer cells. Oncogene 27(Suppl 1):S149-S157. http://dx.doi.org/10.1038/onc.2009.52.
33. Thomas LW, Lam C, Edwards SW. 2010. Mcl-1; the molecular regulation of protein function. FEBS Lett 584:2981-2989. http://dx.doi.org/10.1016/j.febslet.2010.05.061.
34. Flanagan AM, Letai A. 2008. BH3 domains define selective inhibitory interactions with BHRF-1 and KSHV BCL-2. Cell Death Differ 15:580-588. http://dx.doi.org/10.1038/sj.cdd.4402292.
35. Kvansakul M, Hinds MG. 2013. Structural biology of the Bcl-2 family and its mimicry by viral proteins. Cell Death Dis 4:e909. http://dx.doi.org/10.1038/cddis.2013.436.
36. Ryan JA, Brunelle JK, Letai A. 2010. Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes. Proc Natl Acad Sci U S A 107:12895-12900. http://dx.doi.org/10.1073/pnas.0914878107.
37. Whitelaw DM. 1972. Observations on human monocyte kinetics after pulse labeling. Cell Tissue Kinet 5:311-317.
38. Cheng EH, Nicholas J, Bellows DS, Hayward GS, Guo HG, Reitz MS, Hardwick JM. 1997. A Bcl-2 homolog encoded by Kaposi sarcomaassociated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. Proc Natl Acad Sci U S A 94:690-694. http://dx.doi.org/10.1073/pnas.94.2.690.
39. Jenner RG, Alba MM, Boshoff C, Kellam P. 2001. Kaposi's sarcomaassociated herpesvirus latent and lytic gene expression as revealed byDNA arrays. J Virol 75:891-902. http://dx.doi.org/10.1128/JVI.75.2.891-902.2001.
40. Blasig C, Zietz C, Haar B, Neipel F, Esser S, Brockmeyer NH, Tschachler E, Colombini S, Ensoli B, Sturzl M. 1997. Monocytes in Kaposi's sarcoma lesions are productively infected by human herpesvirus 8. J Virol 71:7963-7968.
41. Schulz TF. 2000. Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8): epidemiology and pathogenesis. J Antimicrob Chemother 45(Suppl T3):15-27. http://dx.doi.org/10.1093/jac/45.suppl_4.15.
42. Staskus KA, Zhong W, Gebhard K, Herndier B, Wang H, Renne R, Beneke J, Pudney J, Anderson DJ, Ganem D, Haase AT. 1997. Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol 71:715-719.
43. Andoniou CE, Andrews DM, Manzur M, Ricciardi-Castagnoli P, Degli-Esposti MA. 2004. A novel checkpoint in the Bcl-2-regulated apoptotic pathway revealed by murine cytomegalovirus infection of dendritic cells. J Cell Biol 166:827-837. http://dx.doi.org/10.1083/jcb.200403010.
44. Roulston A, Marcellus RC, Branton PE. 1999. Viruses and apoptosis. Annu Rev Microbiol 53:577-628. http://dx.doi.org/10.1146/annurev.micro.53.1.577.
45. Goldmacher VS, Bartle LM, Skaletskaya A, Dionne CA, Kedersha NL, Vater CA, Han JW, Lutz RJ, Watanabe S, Cahir McFarland ED, Kieff ED, Mocarski ES, Chittenden T. 1999. A cytomegalovirus-encoded mitochondria-localized inhibitor of apoptosis structurally unrelated to Bcl-2. Proc Natl Acad Sci U S A 96:12536-12541. http://dx.doi.org/10.1073/pnas.96.22.12536.
46. Skaletskaya A, Bartle LM, Chittenden T, McCormick AL, Mocarski ES, Goldmacher VS. 2001. A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation. Proc Natl Acad Sci U S A 98:7829-7834. http://dx.doi.org/10.1073/pnas.141108798.
47. Goldmacher VS. 2002. vMIA, a viral inhibitor of apoptosis targeting mitochondria. Biochimie 84:177-185.http://dx.doi.org/10.1016/S0300-9084(02)01367-6.
48. Chan G, Nogalski MT, Yurochko AD. 2012. Human cytomegalovirus stimulates monocyte-to-macrophage differentiation via the temporal regulation of caspase 3. J Virol 86:10714-10723. http://dx.doi.org/10.1128/JVI.07129-11.
49. Hardwick JM, Lieberman PM, Hayward SD. 1988. A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J Virol 62:2274-2284.
50. Pearson GR, Luka J, Petti L, Sample J, Birkenbach M, Braun D, Kieff E. 1987. Identification of an Epstein-Barr virus early gene encoding a second component of the restricted early antigen complex. Virology 160:151-161. http://dx.doi.org/10.1016/0042-6822(87)90055-9.
51. Austin PJ, Flemington E, Yandava CN, Strominger JL, Speck SH. 1988. Complex transcription of the Epstein-Barr virus BamHI fragment H rightward open reading frame 1 (BHRF1) in latently and lytically infected B lymphocytes. Proc Natl Acad Sci U S A 85:3678-3682. http://dx.doi.org/10.1073/pnas.85.11.3678.
52. Bodescot M, Perricaudet M. 1986. Epstein-Barr virus mRNAs produced by alternative splicing. Nucleic Acids Res 14:7103-7114. http://dx.doi.org/10.1093/nar/14.17.7103.
53. Kelly GL, Long HM, Stylianou J, Thomas WA, Leese A, Bell AI, Bornkamm GW, Mautner J, Rickinson AB, Rowe M. 2009. An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in Burkitt lymphomagenesis: the Wp/BHRF1 link. PLoS Pathog 5:e1000341. http://dx.doi.org/10.1371/journal.ppat.1000341.
54. Abulwerdi FA, Liao C, Mady AS, Gavin J, Shen C, Cierpicki T, Stuckey JA, Showalter HD, Nikolovska-Coleska Z. 2014. 3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation. J Med Chem 57:4111-4133. http://dx.doi.org/10.1021/jm500010b.
55. Cohen NA, Stewart ML, Gavathiotis E, Tepper JL, Bruekner SR, Koss B, Opferman JT, Walensky LD. 2012. A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival. Chem Biol 19:1175-1186. http://dx.doi.org/10.1016/j.chembiol.2012.07.018.
56. Mohammad RM, Goustin AS, Aboukameel A, Chen B, Banerjee S, Wang G, Nikolovska-Coleska Z, Wang S, Al-Katib A. 2007. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res 13:2226-2235. http://dx.doi.org/10.1158/1078-0432.CCR-06-1574.
57. Wang G, Nikolovska-Coleska Z, Yang CY, Wang R, Tang G, Guo J, Shangary S, Qiu S, Gao W, Yang D, Meagher J, Stuckey J, Krajewski K, Jiang S, Roller PP, Abaan HO, Tomita Y, Wang S. 2006. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 49:6139-6142. http://dx.doi.org/10.1021/jm060460o.
58. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH. 2005. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681. http://dx.doi.org/10.1038/nature03579.
59. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerickhouse RA, Rosenberg SH, Elmore SW. 2013. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208. http://dx.doi.org/10.1038/nm.3048.
60. Polster BM, Pevsner J, Hardwick JM. 2004. Viral Bcl-2 homologs and their role in virus replication and associated diseases. Biochim Biophys Acta 1644:211-227. http://dx.doi.org/10.1016/j.bbamcr.2003.11.001.
61. Pierceall WE, Kornblau SM, Carlson NE, Huang X, Blake N, Lena R, Elashoff M, Konopleva M, Cardone MH, Andreeff M. 2013. BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia. Mol Cancer Ther 12:2940-2949. http://dx.doi.org/10.1158/1535-7163.MCT-13-0692.
62. Pierceall WE, Warner SL, Lena RJ, Doykan C, Blake N, Elashoff M, Hoff DV, Bearss DJ, Cardone MH, Andritsos L, Byrd JC, Lanasa MC, Grever MR, Johnson AJ. 2014. Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response. Leukemia 28:2251-2254. http://dx.doi.org/10.1038/leu.2014.206.
63. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. 2007. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 12:171-185. http://dx.doi.org/10.1016/j.ccr.2007.07.001.